

News Article downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009
Read [Elusys's Anthrax Anti-Toxin, Anthim\(TM\), Enters Second Phase I Clinical Study](#) on
BioPortfolio.com (<http://www.bioportfolio.com/news/Elusys.html>)

Elusys's Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

Monday 20th of April 2009 13:40

BioPortfolio no longer holds the full text of this article in PDF form.

[Click Here To Read BioPortfolio's Web Page on Elusys's Anthrax Anti-Toxin, Anthim\(TM\), Enters Second Phase I Clinical Study](#)

- [Elusys' Anthim Dramatically Improves Survival of Animals Treated ...](#) 22 Apr 2008 ... *Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate Study* **Elusys Therapeutics, Inc. (Elusys)**, a privately-held ...
http://www.drugs.com/clinical_trials/elusys-anthim-dramatica...
- [Elusys Presents Positive Data on Anthrax Therapeutic at ICAAC](#) 28 Sep 2006 ... *Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys Therapeutics commented on the presentations, "Anthim has now ...*
<http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...>
- [Elusys' Anthim\(TM\) Dramatically Improves Survival of Animals ...](#) **Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection Single, Intramuscular (IM) Dose, Protects up to 75 ...**
<http://www.reuters.com/article/pressRelease/idUS183155+22-Ap...>
- [Elusys' Anthrax Drug, Anthim\(TM\), Superior to Antibiotic as a Post ...](#) 16 Feb 2006 ... 16 /PRNewswire/ -- *Today, at the 4th Annual American Society of Microbiology Biodefense Research Conference in Washington DC, Elusys ...*
<http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...>
- [Elusys Therapeutics Appoints Robert Gundel as Vice President of ...](#) *PINE BROOK, NJ, March 10 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies ...*
<http://www.reuters.com/article/pressRelease/idUS108807+10-Ma...>
- [Elusys Therapeutics Successfully Completes Human Clinical Study of ...](#) *Fast-Track Anthrax*

*Therapeutic Safe and Well Tolerated PINE BROOK, N.J., March 29 /PRNewswire/ -- **Elusys Therapeutics Inc.**, a privately-held ...*

<http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...>

- [Adeona Pharmaceuticals, Inc. \(AEN\) Officers | Stocks | Reuters.com](#) *Mr. Wolf has been a founder of **Elusys Therapeutics, Inc.**, an antibody-based ... Mr. Wolf currently sits on the board of **Elusys Therapeutics** and Netli, ...*
<http://www.reuters.com/finance/stocks/officerProfile?symbol=...>
- [Elusys' Anthrax Anti-Toxin, Anthim\(TM\), Enters Second Phase I ...](#) ***Elusys**, a private company based in Pine Brook, New Jersey , is focused on the development of ... Contact: Debra Duffy 973 808 0222 x212 dduffy@**elusys**.com ...*
<http://www.prnewswire.com/news-releases/elusys-anthrax-anti-...>
- [Celldex Therapeutics, Inc. \(CLDX.O\) Officers | Stocks | Reuters.com](#) *Before joining Optherion, Mr. Elston was with **Elusys Therapeutics** where he raised ... Before joining **Elusys**, Mr. Elston was Chief Financial Officer of ...*
<http://www.reuters.com/finance/stocks/officerProfile?symbol=...>
- [MedImmune Licenses **Elusys Therapeutics'** Technology for Use in ...](#) *20 Apr 2006 ... "We look forward to investigating **Elusys'** proprietary HP Antibodies with the hope that our efforts will lead to new treatment and prevention ...*
<http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...>

Above results from a Google Custom Search Engine. [Search on BioPortfolio](#)

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

